(Q42945644)

11 November 2017

title

Loss of the matriptase inhibitor HAI-2 during prostate cancer progression (English)

1 reference

11 November 2017

Loss of the matriptase inhibitor HAI‐2 during prostate cancer progression (English)

1 reference

17 June 2024

1 reference

Christopher Bergum

1

1 reference

11 November 2017

Karin List

2

1 reference

11 November 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20687215

reference URL

17 June 2024

publication date

1 September 2010

1 reference

11 November 2017

15 September 2010

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20687215

reference URL

full work available at URL

17 June 2024

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fpros.21177

1 reference

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.21177

17 June 2024

1 reference

17 June 2024

1 reference

11 November 2017

volume

70

1 reference

11 November 2017

issue

13

1 reference

11 November 2017

page(s)

1422-1428

1 reference

Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor

11 November 2017

cites work

1

1 reference

Identification and cloning of human placental bikunin, a novel serine protease inhibitor containing two Kunitz domains

17 June 2024

2

1 reference

Epigenetic inactivation and tumor suppressor activity of HAI-2/SPINT2 in gastric cancer

17 June 2024

3

1 reference

HAI-2 is epigenetically downregulated in human hepatocellular carcinoma, and its Kunitz domain type 1 is critical for anti-invasive functions.

17 June 2024

4

1 reference

An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma

17 June 2024

5

1 reference

Reduced expression of hepatocyte growth factor activator inhibitor type-2/placental bikunin (HAI-2/PB) in human glioblastomas: implication for anti-invasive role of HAI-2/PB in glioblastoma cells

17 June 2024

6

1 reference

Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.

17 June 2024

7

1 reference

Mutations in SPINT2 cause a syndromic form of congenital sodium diarrhea

17 June 2024

9

1 reference

Ichthyosis, follicular atrophoderma, and hypotrichosis caused by mutations in ST14 is associated with impaired profilaggrin processing

17 June 2024

10

1 reference

Autosomal recessive ichthyosis with hypotrichosis caused by a mutation in ST14, encoding type II transmembrane serine protease matriptase

17 June 2024

11

1 reference

Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis

17 June 2024

12

1 reference

Delineation of matriptase protein expression by enzymatic gene trapping suggests diverging roles in barrier function, hair formation, and squamous cell carcinogenesis

17 June 2024

13

1 reference

Epithelial integrity is maintained by a matriptase-dependent proteolytic pathway

17 June 2024

14

1 reference

Membrane-anchored serine protease matriptase regulates epithelial barrier formation and permeability in the intestine

17 June 2024

15

1 reference

Matriptase: a culprit in cancer?

17 June 2024

16

1 reference

Matriptase-dependent cell surface proteolysis in epithelial development and pathogenesis

17 June 2024

17

1 reference

Type II transmembrane serine proteases

17 June 2024

18

1 reference

Matriptase and its putative role in cancer

17 June 2024

19

1 reference

Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation

17 June 2024

20

1 reference

Potent inhibition and global co-localization implicate the transmembrane Kunitz-type serine protease inhibitor hepatocyte growth factor activator inhibitor-2 in the regulation of epithelial matriptase activity

17 June 2024

21

1 reference

Upregulation of HGF activator inhibitor type 1 but not type 2 along with regeneration of intestinal mucosa

17 June 2024

22

1 reference

Expression of hepatocyte growth factor activator inhibitor type 2 (HAI-2) in human testis: identification of a distinct transcription start site for the HAI-2 gene in testis

17 June 2024

23

1 reference

Hepatocyte growth factor activator inhibitor types 1 and 2 are expressed by tubular epithelium in kidney and down-regulated in renal cell carcinoma

17 June 2024

24

1 reference

Initiation of plasminogen activation on the surface of monocytes expressing the type II transmembrane serine protease matriptase

17 June 2024

25

1 reference

Regulation of cell surface protease matriptase by HAI2 is essential for placental development, neural tube closure and embryonic survival in mice

17 June 2024

26

1 reference

A novel biomarker for staging human prostate adenocarcinoma: overexpression of matriptase with concomitant loss of its inhibitor, hepatocyte growth factor activator inhibitor-1.

17 June 2024

27

1 reference

Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues

17 June 2024

28

1 reference

In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma

17 June 2024

30

1 reference

Polarized epithelial cells secrete matriptase as a consequence of zymogen activation and HAI-1-mediated inhibition

17 June 2024

31

1 reference

Serum hepatocyte growth factor activator inhibitor type I (HAI-I) and type 2 (HAI-2) in prostate cancer

17 June 2024

32

1 reference

Characterization of placental bikunin, a novel human serine protease inhibitor

17 June 2024

33

1 reference

Hepatocyte growth factor is a preferred in vitro substrate for human hepsin, a membrane-anchored serine protease implicated in prostate and ovarian cancers

17 June 2024

34

1 reference

Hepsin activates pro-hepatocyte growth factor and is inhibited by hepatocyte growth factor activator inhibitor-1B (HAI-1B) and HAI-2.

17 June 2024

35

1 reference

Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 2

17 June 2024

36

1 reference

Matriptase inhibition by hepatocyte growth factor activator inhibitor-1 is essential for placental development

17 June 2024

37

1 reference

Loss of matriptase suppression underlies spint1 mutation-associated ichthyosis and postnatal lethality

17 June 2024

38

1 reference

Protein expression of matriptase and its cognate inhibitor HAI-1 in human prostate cancer: a tissue microarray and automated quantitative analysis

17 June 2024

39

1 reference

Matriptase activation and shedding with HAI-1 is induced by steroid sex hormones in human prostate cancer cells, but not in breast cancer cells.

17 June 2024

40

1 reference

Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue

17 June 2024

41

1 reference

Prostasin induces protease-dependent and independent molecular changes in the human prostate carcinoma cell line PC-3

17 June 2024

43

1 reference

The hepatocyte growth factor regulatory factors in human breast cancer

17 June 2024

45

1 reference

Hepsin promotes prostate cancer progression and metastasis

17 June 2024

46

1 reference

17 June 2024

Identifiers

DOI

10.1002/PROS.21177

1 reference

11 November 2017

1 reference